Predict your next investment

HEALTHCARE | Biotechnology
adagiotx.com

See what CB Insights has to offer

Founded Year

2020

Stage

IPO | IPO

Total Raised

$466M

Date of IPO

8/6/2021

About Adagio Therapeutics

Adagio Therapeutics (NASDAQ: ADGI) develops antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses.

Adagio Therapeutics Headquarter Location

303 Wyman Street Suite 300

Waltham, Massachusetts, 02451,

United States

781-819-0080

Latest Adagio Therapeutics News

Biocon Biologics, Serum Institute Life Sciences enter strategic alliance

Sep 17, 2021

A+ Bengaluru (Karnataka) [India], Sep 17 (ANI): Biocon Biologics Ltd (BBL) and Serum Institute Life Sciences (SILS) have announced a strategic alliance in a bid to make a significant impact on global healthcare through vaccines and biologics. Under the terms of agreement, BBL will offer 15 per cent stake to SILS at a post-money valuation of 4.9 billion dollars (about Rs 35,980 crore) for which it will get committed access to a 100 million doses of vaccines per annum for 15 years. This will be primarily from SILS’s upcoming vaccine facility in Pune with commercialisation rights of the SILS vaccine portfolio (including Covid-19 vaccines) for global markets. BBL will generate a committed revenue stream and related margins starting H2 FY23. Adar Poonawalla will have a board seat in BBL. In addition to vaccines, the strategic alliance will also develop antibodies targeting several infectious diseases like dengue and HIV. The two companies will enter service level agreements for manufacturing and distribution of the vaccines and antibodies. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon and Biocon Biologics, said the alliance will complement the strengths and resources of two leading players in vaccines and biologics. “Our shared vision of building large scale businesses having global impact makes it a unique and synergistic value creation opportunity,” she said in a statement. Adar Poonawalla, CEO of Serum Institute of India, said: “We look forward to complementing each other’s capabilities and capacities in vaccines and biologics, with the objective of addressing inequitable access both in emerging and developed markets for life saving vaccines and biologics.” Vaccines are a complementary business fit to BBL and provide a new dimension to its effort in improving global healthcare. Most recently, BBL announced a manufacturing and commercialisation partnership in select emerging markets with Boston-based Adagio Therapeutics Inc for ADG20, a novel Covid-19 antibody therapy. These collaborations support Biocon Biologics’ intent of straddling on both infectious and non-communicable diseases in its quest to impact global health. BBL will also establish at its cost a vaccine R&D division to support the strategic alliance in developing both vaccines and biologics for communicable diseases. Additionally, wherever possible, it will make available its cell culture and sterile fill and finish capacities for vaccine production under the strategic alliance. Biocon Biologics will issue shares and receive the contemplated rights through a merger with Covidshield Technologies Pvt Ltd (CTPL), a wholly owned subsidiary of SILS, on customary closing conditions and receipt of regulatory approvals. (ANI) This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content. Subscribe to our channels on YouTube & Telegram Why news media is in crisis & How you can fix it India needs free, fair, non-hyphenated and questioning journalism even more as it faces multiple crises. But the news media is in a crisis of its own. There have been brutal layoffs and pay-cuts. The best of journalism is shrinking, yielding to crude prime-time spectacle. ThePrint has the finest young reporters, columnists and editors working for it. Sustaining journalism of this quality needs smart and thinking people like you to pay for it. Whether you live in India or overseas, you can do it here .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Adagio Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Adagio Therapeutics in 1 CB Insights research brief, most recently on Aug 5, 2021.

Expert Collections containing Adagio Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Adagio Therapeutics is included in 2 Expert Collections, including Infectious Disease.

I

Infectious Disease

2,222 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Adagio Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Adagio Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.